Researchers have discovered how dormant pancreatic cancer cells manipulate their surroundings to evade CAR T-cell therapy, identifying a potential therapeutic target for overcoming treatment resistance.
Protein damage could provide a valuable readout for evaluating potential anti-ageing therapies, but reducing complex biological responses to a single score raises important questions about interpretation and validation.
The PsychAD Consortium is using human genetics, single-cell genomics and automated screening to pinpoint potential drug targets for Alzheimer’s disease and investigate their therapeutic potential.
Making better decisions in drug discovery is not down to implementing more tools. Here, Dr Harsh Shah reveals why teams must start by defining the scientific question.
Patients with multiple myeloma who develop a rare but life-threatening gastrointestinal complication following CAR T cell therapy show more than 100 times the average level of long-term CAR T-cell persistence in their bloodstream, MD Anderson researchers report.
A liver-targeted siRNA therapy developed at Duke University has demonstrated preclinical efficacy in mouse models of glutaric aciduria type I.
A study led by the Josep Carreras Leukaemia Research Institute has uncovered how cancer cells manage formaldehyde toxicity without compromising their defences against ferroptosis.
A genetically attenuated strain of Salmonella Typhimurium carrying both a pro-apoptotic protein and immune-stimulating epitopes has demonstrated significant reductions in tumour growth and metastatic spread in preclinical models of aggressive breast cancer.
Laboratory automation in drug discovery can increase the number of compounds teams screen. But how do researchers decide which results are worth following up? In Lab Automation 2026, six researchers and industry specialists share practical lessons on validating screening hits, improving reproducibility in complex cell assays and deciding where automation can make the greatest difference.
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.